A sprinkling of Indian firms docked in at the J.P. Morgan Healthcare Conference 2024 outlining what to expect amid industry headwinds, geopolitical tensions and an election year on the home market. (Also see "J.P. Morgan 2024: Optimism With An Undercurrent Of Tension" - Scrip, 11 January, 2024.)
J.P. Morgan: Serial Acquirer JB Chemicals Talks Strategy, Making ‘Big Brands Bigger’
Private equity-controlled J B Chemicals and Pharmaceuticals, which recently snapped up a basket of ophthalmology brands from Novartis in India, expects to drive momentum to make key product franchises bigger and stronger, while also building on the CDMO business.
More from J.P. Morgan
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
• By
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.